Friday, June 19, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 41 of 1,261
  1. US 12310943

    Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders

    Amazentis SA · Granted May 27, 2025 · Expires May 22, 2045

    granted
  2. US 12310968

    Chiral diaryl macrocycles and uses thereof

    TURNING POINT THERAPEUTICS, INC. · Granted May 27, 2025 · Expires May 22, 2045

    granted
  3. US 12310954

    Salivary gland regeneration

    The Regents of the University of California · Granted May 27, 2025 · Expires May 22, 2045

    granted
  4. US 12310956

    Topical roflumilast formulation having improved delivery and plasma half-life

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted May 27, 2025 · Expires May 22, 2045

    granted
  5. US 12310965

    Treatment of cancer utilizing an identified adenosine fingerprint

    Arcus Biosciences, Inc. · Granted May 27, 2025 · Expires May 22, 2045

    granted
  6. US 12310997

    Compositions and methods of treating ocular diseases

    The Regents of the University of California · Granted May 27, 2025 · Expires May 22, 2045

    granted
  7. US 12310992

    Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells

    United Therapeutics Corporation · Granted May 27, 2025 · Expires May 22, 2045

    granted
  8. US 12311016

    Biomarkers and immunogenic compositions for filarial parasites

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted May 27, 2025 · Expires May 22, 2045

    granted
  9. US 12311030

    Antibody-sting agonist conjugates and their use in immunotherapy

    The Board of Regents of the University of Texas System · Granted May 27, 2025 · Expires May 22, 2045

    granted
  10. US 12311053

    Nanotube-vesicle compositions and uses thereof

    The Regents of the University of California · Granted May 27, 2025 · Expires May 22, 2045

    granted
  11. WO 2025106633

    INHIBITEURS DE TYK2

    BIOGEN MA INC [US] · Granted May 22, 2025 · Expires May 17, 2045

    granted
  12. US 12304907

    Compounds and methods of use

    Tango Therapeutics, Inc. · Granted May 20, 2025 · Expires May 15, 2045

    granted
  13. US 12305189

    Compositions and methods for delivery of AAV

    VOYAGER THERAPEUTICS, INC. · Granted May 20, 2025 · Expires May 15, 2045

    granted
  14. US 12303482

    Levodopa dosing regimen

    AMNEAL PHARMACEUTICALS LLC · Granted May 20, 2025 · Expires May 15, 2045

    granted
  15. US 12304968

    T-cells expressing anti-LIV1 chimeric antigen receptor

    CRISPR THERAPEUTICS AG · Granted May 20, 2025 · Expires May 15, 2045

    granted
  16. US 12303602

    Compositions, methods and uses for thermally stable multi-targeted antigens

    The Regents of the University of Colorado, a Body Corporate · Granted May 20, 2025 · Expires May 15, 2045

    granted
  17. US 12303551

    Cellular immunotherapy compositions and uses thereof

    Cero Therapeutics Holdings, Inc. · Granted May 20, 2025 · Expires May 15, 2045

    granted
  18. US 12304898

    Quinolyl-containing compound and pharmaceutical composition, and use thereof

    PrimeGene (Beijing) Co., Ltd. · Granted May 20, 2025 · Expires May 15, 2045

    granted
  19. US 12303724

    Non-adult human dosing of anti-CD30 antibody-drug conjugates for treatment of hematological or lymphoid cancer

    Takeda Pharmaceutical Company Limited · Granted May 20, 2025 · Expires May 15, 2045

    granted
  20. US 12304969

    Factor XI A2 domain-binding antibodies and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted May 20, 2025 · Expires May 15, 2045

    granted
  21. US 12303479

    Chloride intracellular channel 1 for regulation of food intake

    The Regents of the University of California · Granted May 20, 2025 · Expires May 15, 2045

    granted
  22. US 12304912

    Fused bicyclic RAF inhibitors and methods for use thereof

    Jazz Pharmaceuticals Ireland Limited · Granted May 20, 2025 · Expires May 15, 2045

    granted
  23. US 12304942

    Cell comprising a chimeric antigen receptor or a transgenic T-cell receptor and comprising a chimeric TNF receptor

    AUTOLUS LIMITED · Granted May 20, 2025 · Expires May 15, 2045

    granted
  24. US 12304964

    CD38 modulating antibody

    BLACK BELT THERAPEUTICS LIMITED · Granted May 20, 2025 · Expires May 15, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.